Vaxcyte's Q3 Loss Beats Estimates; VAX-31 BLA Filing Slated for 1H 2028
PCVX sits 65% above its 52-week low of $39.87.
Summary
Vaxcyte posted a Q3 net loss of $297.06 million, narrower than the $310.72 million consensus from eight analysts, with operating expenses up 27% year over year to $308.27 million on VAX-31 Phase 3 trial, manufacturing and personnel costs. The company now guides to OPUS-2 and OPUS-3 Phase 3 results in the first half of 2027, VAX-31 infant Phase 2 topline data by the end of that same half, and a BLA submission for the adult indication in the first half of 2028. This follows the October 5 OPUS-1 win, where VAX-31 met all primary immunogenicity and safety endpoints, and the roughly $1.1 billion raised in the concurrent equity and convertible offerings that closed October 9. The cash position is the story: about $3.4 billion pro forma gives Vaxcyte room to fund the remaining Phase 3 readouts and build out manufacturing without another raise. The 2028 filing date is the key number — it sets the commercial timeline for the adult franchise and frames how long the market waits before revenue.
At the time of this announcement, PCVX was trading at $65.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.3B. The 52-week trading range was $39.87 to $90.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.